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Key messages: 
 Essential medicines for cardiovascular diseases, tuberculosis, and zinc for the management 
of diarrhoea were commonly compounded for children in a sample of seven hospitals in 
Nigeria in 2011; signifying poor access to these medicines. These medicines were found to 
be available in age-appropriate formulations in other countries.  
 
 In order to improve access to medicines for young children, the regulatory agency can 
ensure that age-appropriate medicines available outside Nigeria are granted expedited 
import status, or accelerated product registration. The inclusion of age-appropriate 
formulations for children in the country’s essential medicines list, and the local 
manufacturing of these medicines would improve access in the long-term.   
 
 There is need for the establishment of national guidelines for better quality and safer 
compounding.  A formulary for compounded products should also be produced.  
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ABSTRACT 
Policies to improve access to medicines for children in Nigeria do not include compounding source of 
medicines. Compounding is often applied as a last resort in health institutions to provide age-
appropriate formulations of medicines usually for oral use in young children; but it bears some risk. 
Some countries have adopted policies aimed at reducing the risk based on available data. There is 
not much data for Nigeria. This retrospective study examined compounding records from January to 
December 2011 in a sample of seven hospitals to describe what medicines for oral use were 
commonly compounded in Nigeria. It then determined if these medicines were commercially 
available in forms suitable for use in children in selected countries – the United Kingdom, United 
States, and India. The study found that out of 2845 items compounded, over 65 % were medicines 
for cardiovascular conditions, diarrhoea, or tuberculosis. The main reason (96 %, n=2399) for 
compounding was the unavailability of age-appropriate formulations. Medicines were almost all 
compounded using simple syrup, vitamin C or vitamin B syrups as suspending vehicles. Final 
products were all oral liquids. Comprehensive stability testing was not reported for the products. 
Almost all of the commonly compounded medicines were found to be commercially available in 
dosage forms suitable for use in children in the selected countries. These medicines were all listed in 
the World Health Organization Essential Medicines List for children as well as in the current edition 
of the Essential Medicines List of Nigeria. The fact that they were compounded highlights the need 
for improved access to age-appropriate dosage forms for children in Nigeria. The study recommends 
policy expansion through a three-pronged approach to improving access:  improve supply through 
facilitated importation/ accelerated product registration, or by in-country manufacturing; rational 
drug use including therapeutic substitution and establishment of a national formulary for 
compounding.  
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INTRODUCTION 
In September 2015, the successor programme to the Millennium Development Goals (MDGs), the 
Sustainable Development Goals or SDGs, which charts a new global development agenda for the 
next 15 years was adopted (United Nations, 2015a). One of the eight goals of the MDGs – MDG 4 – 
was the reduction of under-5 mortality by two-thirds based on 1990 figures, with improving access 
to medicines for children being one of the ways to achieving this goal (United Nations, 2015b). 
However, in 2014 it was recognized that Nigeria was not on track to achieving MDG 4, at least not 
until 2022 (Umar and Osinusi, 2014).  As the world looks beyond 2015, more effort is needed to 
ensure that Nigeria achieves sustainable access to medicines for children. 
Within fifteen years from 2000 when the original MDGs were formulated, a number of policies and 
initiatives were announced to improve access to medicines for children. One such initiative was the 
Essential Medicines List for children up to 12 years (EMLc) produced by the World Health 
Organization (WHO) in 2007 (Briane, 2007). This list was built on the framework of the Essential 
Medicines List introduced by the WHO in 1977 and was intended to serve as a template formulary 
for developing countries to guide the selection of medicines for paediatric conditions of public 
health importance. The aim of the EMLc which is reviewed biennially is that health facilities should 
have these medicines at all times: these medicines should be accessible (Sitanshu, et al., 2010; WHO, 
2011a). Access is a multidimensional concept covering physical availability, geographical access, 
affordability, acceptability, and quality (WHO, 2011b). Age-appropriate medicines are defined as 
medicines which are safe, matched to age or ability, and can deliver the intended dose in a way that 
is acceptable to the patient (Nunn, 2011). In the context of this paper, however, an age-appropriate 
medicine refers to any medicine suitable for administration to children under the age of 5 years. For 
physiological reasons, these children usually cannot safely swallow traditional tablets and capsules, 
and so are conventionally prescribed liquid formulations (Bowles et al., 2010).  Though not 
specifically mentioned in the 2000 agenda, age-appropriateness of medicines for children has since 
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become a necessary consideration in the development of children’s medicines; leading the WHO in 
2008 to recommend Flexible Solid Oral Dosage (FSOD) forms such as dispersible tablets as the most 
preferred (or age-appropriate medicines) for children (WHO, 2011c).  
Children have historically suffered poor access to age-appropriate medicines for a variety of reasons 
mainly due to poor financial returns on developing medicines for children, and ethical concerns (U.S. 
Food and Drug Administration, 2011). Consequently, there is a high incidence of off-label and 
unlicensed use of medicines in children. In 2005, it was estimated that between 45 to 60 % of 
medicines prescribed for children up to 12 years in Europe, were used off-label and unlicensed 
(EMA, 2010). Medicines are used off-label when they are used in doses, or for indications, or 
administered in ways other than contained in their marketing authorization; unlicensed medicines 
are medicines such as ‘specials’ (a UK term to describe medicines without a Marketing Authorization 
but which are produced to GMP standards under the terms of a manufacturing licence issued by the 
regulatory authority) or compounded products for which no marketing authorization exists (Turner 
and Choonara, 1997; Turner, et al., 1999; Neubert, et al., 2008).  
Compounding, also known as extemporaneous preparation or dispensing, has been defined as ‘the 
technique applied by pharmacists to produce medicines from active pharmaceutical ingredients 
(APIs) or using authorized medicines when no commercially available, authorized, age-appropriate 
or adequate dosage form exists’ (WHO, 2014a). It often involves crushing tablets or dispersing the 
contents of capsules in a suspending vehicle. Though recommended as a last resort, it is a common 
practice in hospitals and pharmacies in many parts of the world (Kairuz et al., 2007; Carvalho, et al., 
2008; Giam and McLachlan, 2008; Magalhães, et al., 2015). Although necessary, compounding is not 
without its risks. Indeed, it is recognized as one of the most hazardous activities performed by 
pharmacists in hospitals or community pharmacies; with unlicensed medicines more likely to lead to 
an adverse effect than licensed medicines (Lowey and Jackson, 2008; EMA, 2004; Bellis et al., 2013).   
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In many countries in the developed world, there is information on compounded products and 
practices that have informed policies aimed at improving the quality and safety of compounding. For 
example, in the United Kingdom (UK) the  Handbook of Extemporaneous Preparation setting out 
compounding standards and detailing validated methods for the preparation of 50 commonly 
compounded medicines in UK hospitals was produced in 2010 (Jackson and Lowey, 2010).   In 
addition, the UK pharmacy regulator, the General Pharmaceutical Council, in 2014 produced 
guidance for compounding that sets out five principles to be followed to ensure standards and to 
provide quality assurance for compounded products (General Pharmaceutical Council, 2015). 
Broader concerns about safety have led to regulations. For example, the United States, through the 
Drug Quality and Security Act of 2013, and the European Union, through the Resolution on quality 
and safety assurance requirements for medicinal products prepared in pharmacies for the special 
needs of patients, have produced guidelines to regulate compounding practice (Council of Europe, 
2014; Minghetti et al., 2014; FDA 2015). In contrast, there is lack of information reported publicly for 
compounding in developing countries, especially in Africa; only one personal communication for 
some Anglophone countries is reported (Nunn et al., 2012).  
Nigeria, with an estimated 169 million people in 2012, of which about 30 million (≈ 18 %) are young 
children, is the most populous country in Africa (UNICEF, 2014). As in other developing countries, 
almost a decade after the MDGs were formulated, paediatric access to essential medicines in Nigeria 
remained low (Robertson et al., 2009). In recognition of this, the Nigerian government initiated plans 
and policies to improve access to essential medicines. Two of these are the Essential Medicines 
Scale-up Plan which was introduced in 2011 (Federal Ministry of Health, National Primary Health 
Care Development Agency, 2011), and the Save One Million Lives (SOML) Initiative launched in 2012 
(WHO, 2012). A key focus of both programmes was the scaling up of access to essential medicines.  
In Nigeria, while there is paucity of information on the extent of unlicensed and off-label medicine 
use in children, the available literature suggests that the situation might not be so different. A study 
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carried out in a tertiary hospital and a primary health care facility in Nigeria puts the proportion of 
off-label and unlicensed medicine use in both institutions at 41.9 %, with compounding forming the 
bulk of the unlicensed medicines (Okechukwu and Agbomo, 2009).   
Thus far, there is only one published study on medicines compounded in one tertiary hospital in 
Nigeria (Aghahowa et al., 2013). The medicines compounded, compounding practices and the 
reasons for compounding in other hospitals in different parts of the country is not known. Thus, 
there is a lack of comprehensive data to guide policy aimed at improving compounding.  
The aim of this study was to provide information on compounded medicines and practices in a 
sample of hospitals in Nigeria, and to check the commercial availability of the commonly 
compounded medicines in suitable dosage forms in selected countries. By providing data on 
compounding, and availability, this study hopes to provide a basis for policy developments that 
would improve compounding practice, or paediatric access to age-appropriate medicines, in Nigeria. 
The importance of this work lies in the fact that it is the first attempt to provide comprehensive 
information of compounding in seven selected hospitals with a 50% geographical spread (three out 
of six geopolitical zones) in Nigeria. As such, the information it provides can be considered sufficient 
to guide compounding policy, at least in the short-to-medium term. 
 
METHODS 
Study Design 
The study was a retrospective descriptive survey to identify compounded products and practices in a 
sample of seven hospitals in three out of the six geopolitical zones of Nigeria.  These hospitals were 
spread across four states in these three geographical zones as shown in Figure 1. 
Locations 
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Hospitals surveyed were selected both purposively and based on convenience. Criteria for selection 
included: 
 Presence of a children’s unit (out-patient, in-patient, or emergency wards),  
 Record of compounding, 
 Presence of qualified pharmacists.  
The hospitals were also selected to ensure a wide coverage. In each of the three zones sampled, the 
hospital chosen were either among the foremost, or had large patient turnouts, or was a paediatric 
specialist hospital. Researchers’ work experiences with several of these hospitals also influenced 
their choice. The locations were approved by the authors’ institutions.  
Study instrument 
Medicines for oral use compounded from January to December 2011 were extracted from pharmacy 
records using a semi-structured questionnaire summarized in Table 1. The questionnaire design was 
based on elements adapted from a similar questionnaire for African countries used by the 
Commonwealth Pharmacists Association (unpublished). This questionnaire was vetted by a 
consultant pharmacist with considerable practice experience, and was piloted in one of the locations 
for validation. Questionnaires were mostly completed by the researchers (in five locations) from 
records in the ‘Compounding Book’ of the hospitals.  In the other two locations, they were 
completed by the responsible pharmacists in charge of compounding. Characteristics of medicines 
compounded: active pharmaceutical ingredient (API), starting material, final dosage form, 
compounding or suspending vehicle, and reasons for compounding were noted.  
The therapeutic categories of the 10 most commonly compounded medicines were then identified 
using the Anatomical Therapeutic Chemical (ATC) classification system and also from the EMLc, 3rd 
edition (WHO, 2011a). Information was then entered into a Microsoft Excel database to aid analysis. 
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Data was collected in February and June of 2012, and January and October of 2013 during field trips 
to the country. 
Statistical analysis 
Data was analysed using Microsoft Excel 2013 and presented in terms of descriptive statistics – 
percentages.  
Availability of compounded medicines 
Compendia for the UK, United States (US), India, and Nigeria – the electronic Medicines 
Compendium (Datapharm, 2012), DailyMed (U.S National Library of Medicine), National Formulary 
of India (Indian Pharmacopoeia Commission, 2011), and the Essential Medicines Index, EMDEX 
(Lindoz, 2011) respectively – were then checked for commercial availability of the frequently 
compounded medicines. The WHO EMLc (WHO, 2011a) and the current, 5th, edition of the Nigerian 
Essential Medicines List (NEML)  (Federal Ministry of Health, Nigeria, 2010) was also checked for 
inclusion of the commonly compounded medicines.  
 
 
RESULTS  
Compounding practices: documentation, procedures, starting material, final product, length of 
dispensing, suspending vehicle, containers and dosing devices 
All hospitals had a compounding register (the ‘compounding book’) where compounding records are 
entered. An entry would include prescription information – name of patient, age, body weight, 
medicine(s) and treatment duration; starting materials, formula, and calculation for compounding. 
This entry is double-checked by a senior pharmacist. The compounding and supervisory pharmacists 
both sign the record. The reporting format was basically the same in all locations. In most of the 
hospitals surveyed, these records date back several years. Records for 2011 were chosen to establish 
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a baseline for comparison among locations and to provide a “snapshot” of compounding in the 
country.   
The compounding is usually carried out in a designated space in the pharmacy; this is usually an area 
away from where routine dispensing takes place, a separate room or compounding laboratory.  
Formulae for compounding were mostly empirically derived, that is based on the pharmacist’s 
expert knowledge and not on validated evidence. Products were compounded on a named-patient 
basis.  
The starting material for compounding was usually a tablet or capsule, apart from vitamin D where 
this was a liquid. In all cases, the final product was a liquid oral medicine ranging in volume from     
10 – 200 ml. All products were intended for use in a child. The majority, 85 % (2111/2472), of 
compounded products were dispensed for more than 7 days (usually 14 or 28 days). The length of 
dispensing corresponded to the ‘duration’ of treatment as recorded on the prescription sheet. The 
suspending vehicles were simple syrup BP, vitamin B complex syrup, vitamin C syrup, and water in a 
few cases. For some hospitals, a small amount (5-10 ml) of water was used to mix the crushed tablet 
or capsule content before incorporation in the syrup.  
Some hospitals used amber-coloured glass bottles for dispensing the compounded products, while 
some used transparent plastic bottles. In some hospitals, both glass and plastic bottles were used as 
containers for dispensed products. Dosing devices were not routinely dispensed with the products; 
pharmacists sometimes advised on what dosing device might be suitable, and patients procured 
these separately, as the case may be. 
Medicines compounded: APIs and therapeutic categories 
There were a total of 2845 compounded items comprising several different APIs. The number of APIs 
ranged from two for MDH to 32 for UBTH. The bulk of the compounding, 71 % (2011/2845), took 
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place in two tertiary hospitals – UBTH and LUTH. The number of APIs and the three most frequently 
compounded in each hospital are shown in Table 2.  
Compounded medicines varied with the level of health institution, and with each hospital. In the 
tertiary hospitals, cardiovascular medicines were the most commonly compounded: 54 % 
(602/1115) in LUTH and 43 % (386/896) in UBTH; except in NDUTH where nervous system medicines 
– chlorpromazine, classified as a psycholeptic, which was used clinically for the control of seizures in 
epilepsy and neonatal tetanus, and pyridoxine (classified as a vitamin but used clinically for the 
prevention of nervous system toxicity associated with the use of isoniazid) – were the most 
frequently compounded. With the secondary health institutions, therapeutic category varied with 
the hospital. MSCH compounded mostly antimycobacterials, or anti-TB medicines; ADH mostly the 
mineral supplement zinc (as zinc sulfate which is used to provide zinc supplementation in the 
management of diarrhoea), and MDH mostly the anti-malarial quinine. GHI was different from the 
other secondary health facilities in compounding mostly medicines for cardiovascular conditions as 
in LUTH and UBTH (Table 2).  
Overall, 10 APIs made up the bulk (75.6 %, 2151/2845) of compounding across hospitals. These 
were, in decreasing order of number of preparations made: zinc and furosemide (same total number 
of preparations), rifampicin, isoniazid, digoxin, hydrochlorothiazide, spironolactone, vitamin D, 
propranolol, and pyrazinamide (Table 3). These 10 APIs belonged to three ATC main groups:  
cardiovascular system, anti-infectives for systemic use, and alimentary tract and metabolism. The 
cardiovascular medicines indicated for heart diseases and/or oedema – furosemide, digoxin, 
spironolactone, hydrochlorothiazide, and propranolol (see footnote in Table 3) – were the most 
frequently compounded, making up almost 50 % (47.6 %, 1023/2151).  These were followed by       
anti-infectives for systemic use, or anti-tuberculosis (anti-TB) medicines – rifampicin, isoniazid, and 
pyrazinamide (27.8 %, 598/2151). The alimentary tract and metabolism class – constituted largely 
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(81.7 %, 433/530) of zinc sulfate and vitamin D indicated for the treatment of rickets – made up the 
remaining 24.6 % (530/2151) (Figure 2).  
Reasons for compounding 
In almost every case (96 %, 2309/2399) where a reason was provided, the lack of an age-appropriate 
formulation was the reason given for compounding (Figure 3).  
Availability of commonly compounded medicines in a sample of countries 
Apart from spironolactone, all commonly-compounded APIs were commercially available in suitable 
dosage forms in the selected countries (Table 4). All were listed in both the WHO EMLc and the 
NEML; though the EMLc contained a greater proportion in age-appropriate dosage forms (Table 5). 
 
 
 
DISCUSSION 
The need for a national compounding protocol to ensure safety, efficacy and quality 
These results indicate the need for a national compounding protocol to harmonise compounding 
practice in the country, as has been carried out in other countries. While there were compounding 
registers in all the hospitals surveyed, there is a need to harmonise reporting styles. Some locations 
included the label in the record, but some did not. The process of risk evaluation to include 
substitution with a licensed suitable product if available is not systematically recorded. Even though 
the study was limited to one calendar year, records for the entire year were incomplete in several 
locations. Documentation of compounding records should be brought into line with the WHO 
recommendations (WHO, 2014a).  
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There is the need to match dispensing length with documented stability studies, or based on 
recommendations; but this seems not to be the practice. Only one hospital reported some physical 
stability studies. With no detailed studies, the stability of the compounded medicines are not known; 
and there might be microbial, physical and chemical stability issues. Most of the compounded 
medicines were dispensed for the same length of time as the treatment duration in the prescription 
sheet. For chronic conditions, this length of dispensing corresponded to the period the patient 
would usually return to the hospital for checks/evaluation. Thus, the length of dispensing, or 
‘assigned’ shelf-life, was based on convenience. Jackson and Lowey (2010) recommends dispensing 
compounded products for no more than 7 days, or 2-3 days for potent medicines with narrow 
margins between clinical doses and toxicity (or inefficacy). Similarly, the WHO points-to-consider 
document on compounding recommends dispensing for 2-3 days, with refrigeration, when there are 
no added preservatives; or, alternatively, the addition of simple syrup beyond 65 % w/w which 
might help preserve the products such that they can be dispensed for longer than 3 days (WHO, 
2014a). The use of the syrup-based suspending vehicles in the hospitals surveyed might have been 
based on this understanding. However, research is needed to provide evidence that the preservative 
systems in these syrups remain effective over the length of dispensing; especially where water is 
used for mixing the tablet or capsule before suspending in the syrup (Ghulam et al., 2007). In the 
absence of detailed chemical, microbiological and physical stability studies, it is necessary from the 
point of view of efficacy and safety, that hospitals review all information available and consider 
implementation of the recommendation of dispensing compounded products for only 2 – 3 days; or 
a maximum of 7 days. This should begin with those medicines of NTI such as digoxin. 
As a rule, suitable dosing devices should be dispensed with the compounded product. Dosing devices 
most likely to be used by end-users, where an oral syringe was not dispensed with the product, 
would include graduated spoons or measuring cups supplied with other medicines the child might 
have been prescribed, or household spoons. With household spoons, the dose administered to the 
child might be inaccurate because of the wide variation in the measured volume of medicines with 
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this uncalibrated device (Falagas, et al., 2010). For medicines with NTI such as digoxin, variations 
from the prescribed or intended volume as a result of inaccuracy of the dosing device would mean 
that the child receives a sub-therapeutic or a toxic dose. With such medicines, routinely providing 
the patient with an oral syringe or graduated medicine spoon which are more accurate than the 
common household spoon would minimise this risk (Shonna, et al., 2010; Beckett, et al., 2012).  
The study did not include treatment outcome and any adverse drug reaction experienced by the 
patients. That would have involved clinicians and other members of the healthcare team.  Nigeria 
does not have a specific reporting procedure for compounded products; even though there is a 
general pharmacovigilance reporting system in operation since 2004. However, compounded 
products have been known to have quality and safety issues (Kairuz, et al., 2007; Gudeman, et al., 
2013).  
The commonly compounded medicines were all indicated for paediatric diseases of public health 
importance, signifying that they were essential medicines. Apart from prematurity and                
birth-related complications, the three major causes of death in children under the age of 5 in Nigeria 
are malaria, pneumonia, and diarrhoea: diarrhoea alone accounting for 11 % (some 95 000) deaths 
in 2010 (WHO, 2014b; Umar & Osinusi, 2014). The volume of compounding for zinc reflected this 
burden of diarrhoea. These results illustrate that as at 2011, eleven years after MDG 4 and four 
years to the 2015 target, access to age-appropriate medicines for one of the leading causes of 
mortality and morbidity in children in Nigeria was still inadequate.   
However, some progress has been made. With access to zinc for the management of diarrhoea, the 
situation has improved since 2011. In 2014, the first dispersible tablet formulation of zinc was locally 
produced in Nigeria following a pre-qualification exercise by WHO (initiated and backed by the local 
medicines regulatory agency with the support of government) under the WHO’s prequalification of 
medicines programme (WHOPIR, 2014; WHO, 2014c). It is believed that this local production of the 
age-appropriate dispersible zinc tablets would reduce the need for compounding of this medicine in 
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hospitals. In fact, LUTH, for example, no longer compounds zinc. For malaria, the public-private 
partnership –  Affordable Medicine Facility – malaria Artemisinin Combination Therapies          
(AmFm – ACTs) –  launched in 2011 under the Global Fund for Malaria, TB, and HIV/AIDS led to 
dispersible anti-malarial tablets suitable for use in young children being offered to the public at 
subsidized prices (Ajayi et al., 2013). The finding that only one hospital (MDH) had a record for 
extemporaneous compounding of the anti-malarial quinine may suggest that there was good access 
to the WHO recommended first-line artemisinin-based treatment for malaria. However, most 
patients with malaria would in the first instance take treatment from community pharmacies or 
patent medicine vendors while only very serious cases are treated at tertiary hospitals or secondary 
health facilities as those surveyed (Beyeler, et al. 2015). Thus, the situation with regards to access to 
age-appropriate anti-malarial for children cannot be determined from the survey results.   
With tuberculosis, a triple-drug fixed-dose-combination (FDC) dispersible tablet formulation is 
currently being given out free on the directly observed treatment short-course (DOTs) programme 
which was introduced in 2001 (Erah and Ojieabu, 2009). The fact that anti-TB medicines were still 
being compounded in 2011 might be related to possible temporary logistic difficulties leading to 
stock-outs at the time of the survey. It is to be noted, though, that the FDC anti-TB medicines are not 
all age-appropriate with research being conducted to find suitable products for dosing reasons 
(WHO, 2015). This can be another reason for the compounding of the individual anti-TB medicines.  
Thus, even though the outcomes may not yet be optimal, for the infectious and communicable 
diseases of diarrhoea, malaria, and tuberculosis policy interventions are in place.  
However, the same cannot be said for the provision of medicines for the non-communicable 
cardiovascular diseases. Cardiovascular diseases have usually not been considered with the same 
level of priority as infectious diseases, at least in sub-Saharan Africa countries like Nigeria. However, 
emerging data suggest that their impact on public health is significant (Ogeng’o et al, 2013; Thomas 
et al., 2013). For instance, congestive cardiac failure is reported as a ‘common’ cause of morbidity 
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and mortality among Nigerian children, and accounts for between 5.8 to 9 % of paediatric 
emergency admissions (Oyedeji et al, 2010). The lack of age-appropriate cardiovascular medicines 
for children across the globe is well documented (Yeung et al., 2004; Wimmer et al., 2014). The 
implication of this is that in the near future, there may still be need for compounding of these 
medicines for the non-infectious – but increasingly of public health significance – cardiovascular 
diseases. There is, therefore, the need that policies are developed to meet this emergent situation; 
more so as the SDGs emphasises the control of NCDs. 
Some of the compounded medicines were high risk medicines that that ought not to be 
compounded for reasons of efficacy and safety, both for the patient and the compounding 
pharmacist. For example drugs with narrow therapeutic indices (NTI) such as digoxin where there is 
no assurance that the intended dose would be given; with the therapeutic efficacy consequently in 
question, or possible toxicity with overdose. Others were anti-neoplastic medicines such as 
mercaptopurine (not among the top 10 compounded APIs, and thus not shown here) that require 
protective clothing and handling only in designated areas to avoid contact with the skin and other 
possible adverse effects on the compounding pharmacist. However, based on researcher’s 
observation at the time of the study, there was no evidence that special protective measures were 
adopted or taken when these cytotoxic preparations were compounded. It would be necessary that 
where compounding of these medicines are undertaken, dedicated areas and protective equipment 
should be worn as recommended (WHO, 2014a). 
As seen from the results, local unavailability was the main reason for compounding: this might have 
been due to several factors. One of these might be that in the hospitals, some of the medicines 
compounded might have been stocked-out during the survey period, as noted for the anti-TB 
medicines, suggesting logistics challenges. Another reason could be that medicines available 
elsewhere in suitable dosage forms had not, at the time of the survey, been registered by the local 
medicines regulatory agency; and so were not available in Nigeria as licensed products. This latter 
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reason appeared to have been the case with, for example, furosemide and digoxin. It is encouraging 
to note that some of these medicines that were compounded are now licensed in the country as 
liquid medicines, for example digoxin elixir (National Agency for Food and Drug Administration and 
Control, 2015).  
There is no system whereby hospitals can procure medicines not available in suitable dosage form 
from ‘specials’ manufacturers as it is in UK, for example. So, medicines not available as                   
age-appropriate dosage forms would have to be prepared as required in each hospital. While 
patients have to pay an additional cost for this (for the container, and in some cases, a 
‘compounding charge’), the amount is minimal. The alternative to this would be that the end-user 
either forces the child to swallow the intact dosage form, which can be unsafe, or in many instances 
not possible, or to manipulate the adult dosage form (WHO, 2007). Thus, by compounding, the 
pharmacist provides a useful and much needed service.  
However, there is still the need to ensure availability of other high risks APIs such as furosemide in 
age-appropriate formulations. While this is available as an oral liquid in the selected countries 
surveyed (but not in Nigeria), this liquid has a high alcohol content (10 % w/v) necessary to solubilize 
the API. This high content of alcohol makes it not age-appropriate for neonates or young children. 
Medicines for neonates are not supposed to contain alcohol, and young children less than 5 years 
should not be exposed to alcohol medicines contents or more than 5% w/v (Whittaker, et al., 2009). 
There is thus an urgent need for an age-appropriate formulation of furosemide, preferably as a 
dispersible tablet that could be used in low-resource settings.  
While not within the scope of this work, there did seem to be at least one instance of compounding 
for an off-label indication with chlorpromazine. For the indications for which this medicine was used, 
a licensed product such as diazepam, administered intravenously, orally, or rectally (in children more 
than a year old) using the appropriate formulation would have been a safer alternative. This finding 
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suggests the need for further studies into the rational prescribing and use of medicines for paediatric 
conditions in Nigeria.   
Implications for policy development 
The country can consider a three-pronged policy approach to increasing access to age-appropriate 
medicines for children: increase supply, promote rational drug use and generic substitution and 
establish standards for compounding.  
Firstly, policy expansion, expedited regulatory approvals, and inclusion of suitable medicines in the 
local EML can help to improve supply of age-appropriate medicines. The focus of public health 
policies with regards to access to medicines for children in Nigeria is, understandably, on 
infectious/communicable diseases such as diarrhoea, pneumonia, malaria, HIV/AIDs, and 
tuberculosis. The results from this first multi-centre survey of compounding, however, showed that 
medicines for the non-communicable cardiovascular diseases were being very commonly 
compounded in hospitals. Thus, public health policies should also focus on the provision of these 
medicines in age-appropriate dosage forms. A focus on the provision of age-appropriate medicines 
for both communicable and non-communicable paediatric diseases would be in alignment with the 
SDGs. SDG 3 – which effectively replaces MDGs 4,5 and 6 – aims for the complete eradication of 
communicable diseases in the under-5 while better managing non-communicable diseases (United 
Nations, 2015a).  Age-appropriate dosage forms of medicines that are commonly compounded 
which are available in other countries should be granted expedited import status, or accelerated 
registration in the country, by the local drug regulatory agency, at least in the short-term. It would 
also be necessary to include FSOD forms in the next edition of the country’s Essential Medicines List, 
such that these medicines can be manufactured locally in the long-term. These measures would help 
improve the supply of suitable cardiovascular medicines for children.  
To guide policy formulation and planning, it would be useful if similar surveys as this one are 
conducted at fixed intervals, approximately once a year, to find out what APIs are commonly 
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compounded by a more representative sample of hospitals and to see if these medicines are 
available in suitable dosage forms elsewhere, so that necessary steps can be taken to ensure that 
they are made available locally. These surveys can take the form of selected hospitals in each of the 
six geo-political zones in the country uploading a monthly report of compounded medicines to a 
central coordinating Centre at the local regulatory agency. This would then form a database that can 
inform decisions for improving availability and geographical access to medicines for which age-
appropriate commercial products exist outside the country.   
There is a lack of local data on cost-benefit analysis of hospital compounding of medicines compared 
with procuring the commercially available medicines from countries where they are available. 
Regulatory restrictions may limit the ability of hospitals to make such direct procurements. The 
possibility of quality-qualified designated hospitals in each state providing age-appropriate 
medicines by compounding as a value-added service where suitable medicines are not available, or 
are too expensive, can be explored. Such a cost-benefit analysis could be performed in a future 
study.   
Secondly, rational drug use policies in children should be considered. The national formulary, 
combined with the standard treatment guideline appropriately modified to include age-appropriate 
medicines for children, can be used to guide selection of use of medicines for children. Each hospital 
can also include therapeutic alternatives that are available in age-appropriate dosage forms in their 
local formulary to guide prescribers in the choice of suitable formulations to prescribe for children. 
Therapeutic product substitution as recommended by the WHO guideline on compounding should 
be encouraged. Educational strategies for pharmacists and physicians on the risks inherent in 
compounding and the need to ensure better medicine use in children would also help to ensure 
access to suitable medicines for children and to further improve patient safety.  
Thirdly, quality standards for compounded products and practices should be established. For those 
medicines for which no suitable product exist elsewhere, and with no therapeutic alternatives, and 
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for which compounding is necessary, measures should be put in place to guarantee product quality. 
Recently, more information is becoming publicly available that can guide compounding (Jackson and 
Lowey, 2010; PharmInfoTech; e-drug compounding; extemp.ie; The Hospital for Sick Children, 2014). 
These can be used as reference sources of formulae for compounded medicines, as well as provide 
stability information to guide length of dispensing. The limitation might be that these sources would 
mainly contain products ‘specific’ to local needs with stability data that might not reflect storage 
conditions in Nigeria.  
On 9 December 2014, Nigeria signed the Health Bill into law (Liebschutz, 2014). This Bill seeks, 
among other things, to improve the quality and standard of health care in health institutions in the 
country. It is imperative that a policy framework be fashioned out from this Bill to address 
compounding as a means of providing medicines for children when no suitable commercial 
formulation exists. In line with this, the Government, or the professional body of pharmacists, 
should organize a forum where hospital pharmacists can meet to share information on compounding 
best practices which would lead to the formulation of a national guidance document. This forum 
should also be tasked with the production of a national formulary of compounded medicines. These 
would help to ensure quality and standards of medicines compounded for children in hospitals in 
Nigeria as a means of ensuring paediatric public health.   
Limitations 
A main limitation of this study is its retrospective nature. Compounded products, and practices, 
might have changed in these institutions. Indeed, as earlier noted, dispersible zinc tablets are now 
locally available. What this study showed though was that in many cases where medicines were 
compounded for children in the country for reasons of unavailability, the medicines were actually 
available elsewhere in suitable dosage forms.  
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While efforts were made to ensure a fairly-wide national coverage in the choice of study locations, 
the possibility of selection bias in this approach is acknowledged. However, this potential bias was 
minimized by selecting some of the major hospitals in the three selected geo-political zones; thus 
the study tried to achieve at least a 50% national coverage. 
CONCLUSIONS 
Policies aimed at improving access to medicines in Nigeria have not included compounding as a 
source of medicines for children. In keeping with several other countries, compounding of age-
appropriate medicines for children occurs in local/national hospitals because suitable, licensed 
products are not manufactured or made available in Nigeria. Compounding does not include the 
same quality assurance measures as licensed manufacturing so there are risks that children get a 
poor quality medicine with possible consequences on safety and efficacy. 
When compounding is necessary, a formulary of evaluated monographs should be available to guide 
pharmacists on methods of preparation, simple quality assurance measures, storage and shelf life of 
the product. The use of commercial suspending agents may be costly so there should be research to 
determine an appropriate suspending vehicle that could be manufactured and licensed locally. 
Policy expansion to provide guidance on compounding as a source of medicines for children is 
necessary to safeguard paediatric public health. Nigeria should have a policy on compounding of 
medicines alongside information on the availability of suitable, licensed products for importation 
and should determine those medicines that could best be manufactured and licensed locally. 
Regular review of medicines compounded in Nigerian hospitals would provide information that 
could be used to determine medicines supply policy for Nigerian children. 
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Table 1 Summary of the questionnaire used  
Question Options/Specific items Response Type 
Name of product  a  
Dosage form E.g., syrup, suspension, solution,                 
other (specify) 
b  
Strength of product (mg/ml)  a  
Starting material Raw materials, adult formulation b 
Quantity dispensed  a 
Method of compounding  a 
Source of formula Local formulary, journal, textbook, 
pharmacopoeia, other (specify) 
b 
Container Plastic, glass, other b 
Dosage instructions  a 
Dosing device recommended Spoon, (oral) syringe, other (specify) b 
Expiry date E.g., 5, 7, 14, or 28 days a 
Source of expiry date Local formulary, journal, textbook, 
pharmacopoeia, , other (specify) 
b  
Why was product 
compounded 
No available age-appropriate formulation, 
liquid product out-of-stock, high cost of 
commercial product, other (specify) 
b 
 
Notes: a = open-ended; b = closed with options for comments 
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Table 2 Range of active pharmaceutical ingredients (APIs) and the three most frequently 
compounded in seven hospitals in Nigeria (2011) grouped according to level of hospital 
Level of hospital Name of hospital No. of APIs 
compounded 
Three most frequently compounded 
APIs 
Tertiary University of Benin 
Teaching Hospital 
(UBTH)1 
32 Hydrochlorothiazide 16 % (139/896), 
Spironolactone 14 % (127/896), 
Vitamin D 11 % (97/896). 
 Lagos University 
Teaching Hospital 
(LUTH) 
30 Furosemide 38 % (420/1115), 
Zinc 24 % (264/1115), 
Digoxin 16 % (182/1115). 
 Niger Delta 
University Teaching 
Hospital (NDUTH) 
15 Chlorpromazine 33 % (33/99), 
Pyridoxine 15 % (15/99),       
Ciprofloxacin 12 % (12/99). 
Secondary Massey Street 
Children Hospital 
(MSCH) 
7 Isoniazid 43 % (120/278),         
Rifampicin 40 % (112/278), 
Pyrazinamide 11 % (31/278). 
 General Hospital 
Isolo (GHI) 
4 Spironolactone 53 % (10/19), 
Hydrochlorothiazide 32 % (6/19), 
Furosemide 11 % (2/19). 
 Asokoro District 
Hospital (ADH) 
20 Zinc 35 % (93/266),                   
Nevirapine 14 % (36/266),            
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Calcium 12 % (32/266). 
 Maitama District 
Hospital (MDH) 
2 Quinine 97 % (63/65),                           
Zinc 3 % (2/65). 
Notes: 1. UBTH also provides secondary, and some primary, level health care service (UBTH, 2015). 
Table 3 The 10 most frequently compounded active pharmaceutical ingredients (APIs) with 
therapeutic indication (clinical use) in a sample of seven hospitals in Nigeria in 2011  
No. 
(Rank) 
API Therapeutic 
indication/     
Clinical use 
No. of items 
compounded 
(n) 
% of all 
compounded 
items 
(n/28451) 
1 (1) Zinc Diarrhoea 433 15.2 
2 (1) Furosemide Heart failure 433 15.2 
3 (2) Rifampicin Tuberculosis 263 9.2 
4 (3) Isoniazid Tuberculosis 242 8.5 
5 (4) Digoxin Heart failure 208 7.3 
6 (5) Hydrochlorothiazide Diuretic 149 5.2 
7 (6) Spironolactone Diuretic 138 4.9 
8 (7) Vitamin D Rickets 97 3.4 
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9 (8) Propranolol Migraine2 95 3.3 
10 (9) Pyrazinamide Tuberculosis 93 3.3 
 Total of all 
compounding 
  75.5 
Notes: 1. Total items compounded. 2. Propranolol is classified as an anti-migraine medicine in the 
EMLc but was used in combination with hydrochlorothiazide and spironolactone for cardiovascular 
indications in the survey. 
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Table 4 Commercial availability of the 10 most commonly compounded medicines as age-appropriate dosage1 forms in UK, US, India, and Nigeria (2011) 
API in compounded 
medicine 
Age-appropriate dosage form(s) and strengths available in:  
UK US India Nigeria 
Zinc Not available Not available Dispersible tablets2 Not available3 
Furosemide Oral liquid 20,40, or 50mg/5ml Oral liquid 10, and 40mg/5ml Oral liquid 10mg/ml Not available 
Rifampicin Syrup 100mg/5ml Syrup 100mg/5ml Syrup 100mg/5ml Not available4 
Isoniazid Combination products; none of 
which  is age-appropriate 
50mg/5ml solution Not available Not available 
Digoxin Elixir 50 microgram/ml Oral solution 50 microgram/ml Elixir 50 microgram/ml Not available5 
Hydrochlorothiazide Not available 50mg/5ml solution Not available Not available 
Spironolactone Not available6 Not available Not available Not available 
Vitamin D Available as a combination               
A,D, and C drops 
Ergocalciferol Oral Liquid 
8,000units/ml 
Not available Not available 
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Notes: 1. Age-appropriate dosage forms here include dispersible, soluble, or chewable tablets and oral liquids. Crushable tablets are not included unless 
specifically formulated as such and not used for manipulation purposes. 2. Not listed in the compendia used; but known to be commercially available in 
India. 3. Dispersible tablets currently manufactured locally. 4. Currently available locally as a 100mg/5ml oral syrup. 5. The elixir is now available in Nigeria. 
6. Liquid product available only as ‘specials’ or from importing companies. 
 
 
Propranolol Oral solution 20mg, and 40mg/5ml Oral solution 10mg, and 40mg/5ml Not available Not available 
Pyrazinamide Not available (tablet only) Not available (tablet only) Oral suspension 250mg/5ml Not available 
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Table 5 Dosage forms of the 10 commonly-compounded medicines as listed in the EMLc and NEML, 
with proportions considered age-appropriate for use in young children.                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Tablet or capsule                
 
 API Dosage form(s) listed in 
EMLc, 3rd list, 2011 NEML, 2010 
1 Zinc Solid oral dosage form* Tablet, Oral liquid 
2 Furosemide Tablet, Oral liquid Tablet 
3 Rifampicin Solid oral dosage form*, 
Oral liquid 
Capsule, Tablet 
4 Isoniazid Tablet, Oral liquid Tablet 
5 Digoxin Tablet, Oral liquid Tablet, Oral liquid 
6 Hydrochlorothiazide Tablet (scored) Tablet 
7 Spironolactone Tablet, Oral liquid Tablet 
8 Vitamin D (as ergocalciferol 
or cholecalciferol) 
Solid oral dosage form*, 
Oral liquid 
Capsule, Oral liquid 
9 Propranolol Tablet Tablet 
10 Pyrazinamide Tablet, Oral liquid, 
Dispersible tablet 
Tablet 
 Age-appropriate (%) 7 (70 %) 3 (30 %) 
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Figure 1 Map of Nigeria showing the locations of study sites indicated by the triangles in the six 
geopolitical zones. 
 
Source: www.intechopen.com 
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Figure 2 Therapeutic categories of the 10 most frequently compounded active pharmaceutical 
ingredients making up 75.6 % (2151/2845) of compounding in a sample of seven hospitals in Nigeria 
in 2011.  
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Figure 3 Reasons for compounding (n = 2399) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
